Inclusion of Treprostinil Injection, Teglutik® and Trittico® in the National Reimbursement Drug List

Treprostinil Injection, Teglutik® and Trittico®, the commercialized products of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) have been included for the first time into the updated National Reimbursement Drug List (the “NRDL”) issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group’s Treprostinil Injection and Teglutik® have taken up 2 places thereof. Lee’s Pharm firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordability and accessibility thereof among patients in rare disease and mental health areas.

The release as fetched from its publisher. leespharm.com ↗